Wedbush Issues Positive Outlook for KNSA Earnings

Key Points

• Wedbush Research analysts increased their Q3 2025 earnings per share estimate for Kiniksa Pharmaceuticals International from $0.25 to $0.43, maintaining an "Outperform" rating with a price target of $36.00.
• The company reported a quarterly EPS of $0.23, surpassing analysts' expectations of $0.18, alongside a revenue of $156.80 million, exceeding estimates of $145.21 million.
• Multiple other analysts have raised their price targets for Kiniksa, with Wells Fargo now at $42.00 and Jefferies at $54.00, indicating strong positive sentiment across the board.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) - Investment analysts at Wedbush boosted their Q3 2025 earnings estimates for shares of Kiniksa Pharmaceuticals International in a research report issued to clients and investors on Tuesday, July 29th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $0.43 per share for the quarter, up from their previous forecast of $0.25. Wedbush has a "Outperform" rating and a $36.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals International's current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals International's Q4 2025 earnings at $0.47 EPS, FY2025 earnings at $1.27 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.68 EPS, FY2026 earnings at $2.34 EPS, FY2027 earnings at $3.15 EPS and FY2028 earnings at $3.28 EPS.

KNSA has been the topic of several other reports. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Finally, Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock traded up $0.10 during trading on Friday, hitting $33.05. 694,832 shares of the company traded hands, compared to its average volume of 699,116. Kiniksa Pharmaceuticals International has a 1 year low of $17.82 and a 1 year high of $33.98. The company has a market cap of $2.41 billion, a PE ratio of 826.16 and a beta of 0.14. The stock's 50-day simple moving average is $28.50 and its 200 day simple moving average is $24.25.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, insider Ross Moat sold 27,594 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total value of $800,777.88. Following the transaction, the insider owned 9,415 shares of the company's stock, valued at $273,223.30. This trade represents a 74.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Mark Ragosa sold 18,299 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $28.80, for a total transaction of $527,011.20. Following the completion of the sale, the chief financial officer owned 27,009 shares in the company, valued at $777,859.20. This represents a 40.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 314,709 shares of company stock valued at $9,013,851. 53.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter valued at $301,000. GAMMA Investing LLC grew its holdings in Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $1,184,000. Nuveen Asset Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 7.3% in the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Kiniksa Pharmaceuticals International by 46.3% during the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock valued at $1,381,000 after purchasing an additional 22,096 shares in the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.